Skip to main content

Advances in Therapy

Ausgabe 2/2024

Inhalt (30 Artikel)

Open Access Commentary

Living with Cerebrotendinous Xanthomatosis: Patient, Caregiver, and Expert Perspectives

Robert D. Steiner, Andrea DeBarber, Austin Larson, Bobbi Blanchard, Shawn Laurie, Neel Odedara, Hollisa Rosengrant, Rana Dutta

Open Access Review

Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases

Jonathan Kay, Raymond K. Cross, Steven R. Feldman, Younjin Park, Stephen B. Hanauer

Open Access Review

Machine Learning Approaches to Predict Asthma Exacerbations: A Narrative Review

Nestor A. Molfino, Gianluca Turcatel, Daniel Riskin

Review

Liver Dysfunction in Adult Hemophagocytic Lymphohistiocytosis: A Narrative Review

Muaaz Masood, Asma Siddique, Rajesh Krishnamoorthi, Richard A. Kozarek

Open Access Review

Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials

Eduardo Mysler, Gerd R. Burmester, Christopher D. Saffore, John Liu, Lani Wegrzyn, Chelsey Yang, Keith A. Betts, Yan Wang, Alan D. Irvine, Remo Panaccione

Open Access Original Research

The Impact of the COVID-19 Pandemic on Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey

Laurent Peyrin-Biroulet, Karoliina Ylänne, Allyson Sipes, Michelle Segovia, Sean Gardiner, Joseph C. Cappelleri, Amy Mulvey, Remo Panaccione

Open Access Original Research

Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension

Ekkehard Grünig, Franck Rahaghi, Jean Elwing, Carmine Dario Vizza, Joanna Pepke-Zaba, Jieyan Shen, Hua Yao, Antoine Hage, Stephan Rosenkranz, Madelon Vonk, Vijay Balasubramanian, Yang Yuanhua, Zaixin Yu, James Lordan, Linda Cadaret, Rob Grover, Aliou Ousmanou, Scott Seaman, Chunqin Deng, Meredith Broderick, R. James White

Open Access Original Research

The Effects of Safinamide in Chinese and Non-Chinese Patients with Parkinson’s Disease

Carlo Cattaneo, Jaime Kulisevsky

Open Access Original Research

Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B

Benoit Guillet, Songkai Yan, Becky Hooper, Douglass Drelich, Jason Steenkamp, Radovan Tomic, Maria Elisa Mancuso

Open Access Original Research

Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study

Shuhua Yi, Zhen Cai, Yu Hu, Aili He, Sujun Gao, Qian Li, Linlin Sha, Nating Zhang, Yupeng Ren, Xue Gai, Xue Yang, Rui Qin, Lugui Qiu

Original Research

Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis

Gia Han Le, Angela T. H. Kwan, Sabrina Wong, Ziji Guo, Kayla M. Teopiz, Sebastian Badulescu, Shakila Meshkat, Giacomo d’Andrea, Roger Ho, Taeho Greg Rhee, Bing Cao, Lee Phan, Joshua D. Rosenblat, Rodrigo B. Mansur, Mehala Subramaniapillai, Roger S. McIntyre

Open Access Original Research

Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

Philippe Moreau, María-Victoria Mateos, Maria Esther Gonzalez Garcia, Hermann Einsele, Valerio De Stefano, Lionel Karlin, Joanne Lindsey-Hill, Britta Besemer, Laure Vincent, Suriya Kirkpatrick, Michel Delforge, Aurore Perrot, Niels W. C. J. van de Donk, Charlotte Pawlyn, Salomon Manier, Xavier Leleu, Joaquin Martinez-Lopez, Francesca Ghilotti, Joris Diels, Raúl Morano, Claire Albrecht, Vadim Strulev, Imène Haddad, Lixia Pei, Rachel Kobos, Jennifer Smit, Mary Slavcev, Alexander Marshall, Katja Weisel

Open Access Original Research

The Effect of β-Blocker Eye Drops on Pulse Rate, Ocular Blood Flow, and Glaucoma Progression: A Retrospective Longitudinal Study

Naoki Kiyota, Yukihiro Shiga, Takahiro Ninomiya, Satoru Tsuda, Kazuko Omodaka, Noriko Himori, Yu Yokoyama, Kyongsun Pak, Toru Nakazawa

Open Access Original Research

Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis

Mei Lu, Loralee B. Rupp, Christina Melkonian, Sheri Trudeau, Yihe G. Daida, Mark A. Schmidt, Stuart C. Gordon

Original Research

Biomarker Testing Journey Among Patients with Advanced Solid Tumors and Treatment Patterns by Homologous Recombination Repair Status: A Clinico-Genomic Database Study

Changxia Shao, Yixin Ren, Heng Zhou, Liam C. Lee, Cai Chen, Elisha J. Dettman, Razvan Cristescu, Alexander Gozman, Fan Jin, Wei Zhou

Original Research

TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort

Sergio D. Cruz-Romero, Sebastián González, José Y. Juez, David S. Becerra, Ana M. Baldión, José A. Hakim, Deyanira González-Devia, Sandra Perdomo, Paula A. Rodríguez-Urrego

Open Access Original Research

Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes

Niall J. Davison, Nicole L. Guthrie, Sarah Medland, Paul Lupinacci, Robert J. Nordyke, Mark A. Berman

Original Research

Glucagon-Like Peptide 1 (GLP-1) Receptor Variants and Glycemic Response to Liraglutide: A Pharmacogenetics Study in Iranian People with Type 2 Diabetes Mellitus

Maryam Eghbali, Fariba Alaei-Shahmiri, Nahid Hashemi-Madani, Zahra Emami, Ladan Mostafavi, Mojtaba Malek, Mohammad E. Khamseh

Open Access Brief Report

The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis

Awad Alshahrani, Naji Kholaif, Mutaz Al-Khnifsawi, Hawazen Zarif, Moeber Mahzari

Case Series

Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study

Hongfan Zhao, Zhicheng Xu, Chengbin Li, Tong Xu, Jingliang Zhang, Jianhua Jiao, Bo Yang, Rongliang Qin, Lijun Yang, Weijun Qin, Yuming Jing

Open Access Case Series

Oleogel-S10 in Dystrophic Epidermolysis Bullosa: A Case Series Evaluating the Impact on Wound Burden Over Two Years

Mauricio Torres Pradilla, Erick Álvarez, Mónica Novoa, Ivonne Lozano, Maribel Trujillo

Open Access Correction

Correction to: Relationship Between Asthma Control Status and Health-Related Quality of Life in Japan: A Cross-Sectional Mixed-Methods Study

Hiroyuki Nagase, Risako Ito, Moe Ishii, Hideki Shibata, Shintaro Suo, Isao Mukai, Shiyuan Zhang, Kieran J. Rothnie, Claire Trennery, Liza Yuanita, Takeo Ishii

Open Access Correction

Correction to: Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary

Anikó Maráz, Bence Nagy, Tamara Macher, József Jeskó, Erika Tischler, Csaba Csongvai, Mairead Kearney

Open Access Correction

Correction to: A Risk-Based Approach for Safety Case Follow-up of Adverse Event Reports in Pharmacovigilance

Ganesh Kumar Vemula, Pavan Badale, Petros Mavrogenis, Isabelle Lalande-Luesink, Michal Borkowski, David John Lewis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.